Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Real-time Estimate Cboe BZX 10:11:20 2024-04-16 am EDT 5-day change 1st Jan Change
145.1 USD -1.66% Intraday chart for Johnson & Johnson -5.06% -7.76%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Trending : Johnson & Johnson 1Q Adjust Earnings Beat Forecasts as Company Raises Dividend DJ
Sector Update: Health Care Stocks Mixed Premarket Tuesday MT
Market sentiment sours Our Logo
Johnson & Johnson Narrows Full-Year Outlook as First-Quarter Sales Miss Street Views MT
Wall St set for higher open as upbeat earnings obscure Mideast jitters RE
Johnson & Johnson: EPS up to $2.20 in Q1 CF
Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug MT
Fed Outlook, Overseas Markets Cap Wall Street Pre-Bell; Asia, Europe Lower MT
Stock Futures Decline Pre-Bell as Traders Await More Earnings; Asia, Europe Down MT
Johnson & Johnson's Q1 Adjusted Earnings, Revenue Increase; 2024 Guidance Narrowed; Quarterly Dividend Lifted MT
Johnson & Johnson 1Q Sales Rise on U.S. Growth, Cuts Adjusted EPS Outlook DJ
Johnson & Johnson Raises Quarterly Dividend by 4.2% to $1.24 DJ
Earnings Flash (JNJ) JOHNSON & JOHNSON Posts Q1 Revenue $21.38B, vs. Street Est of $21.39B MT
Earnings Flash (JNJ) JOHNSON & JOHNSON Posts Q1 EPS $2.71, vs. Street Est of $2.65 MT
North American Morning Briefing : Powell Comments, -2- DJ
Johnson & Johnson Announces Quarterly Dividend, Payable on June 4, 2024 CI
J&J beats first-quarter profit estimates on cancer drugs strength RE
Johnson & Johnson Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Futures ease as bond yields stay elevated amid Middle East tensions RE
MORNING BID EUROPE-Market mood stays sombre RE
MEDIA-Zimbabwe recalls tainted J&J's cough syrup sold in six African nations- Bloomberg News RE
Tanzania, Rwanda Latest to Recall Batch of Johnson & Johnson's Infant Cough Syrup MT
Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... Our Logo
Integer Holdings to Benefit from Pulsed Field Ablation Market Growth, BofA Says MT
Market outlook is uncertain, but optimism prevails Our Logo
Chart Johnson & Johnson
More charts
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
147.6 USD
Average target price
175.4 USD
Spread / Average Target
+18.82%
Consensus
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. News Johnson & Johnson
  5. South Africa Health Regulator Flags First Death Linked to Johnson & Johnson COVID-19 Jab